Picture of Protagonist Therapeutics logo

PTGX — Protagonist Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Protagonist Therapeutics Q3 revenue surges on Takeda payments

Protagonist Therapeutics Q3 revenue surges on Takeda payments


Overview

  • US biopharma firm's Q3 license and collaboration revenue surged on Takeda milestone and opt-out payments

  • Company swung to net income in Q3 from a loss a year earlier; diluted EPS turned positive

  • Company authorized $300 mln share buyback program


Outlook

  • Company expects R&D expenses to rise in late 2026 due to advancing clinical programs

  • Company plans to start Phase 2b study of PN-881 in plaque psoriasis in early Q1 2027

  • Company expects to begin Phase 1 study of oral PN-477o in H1 2027


Result Drivers

  • TAKEDA PAYMENTS - Q3 revenue primarily driven by $200 mln opt-out fee and $75 mln milestone from Takeda after FDA approval of MIMRYLO

  • R&D SPENDING - Higher R&D expenses mainly due to clinical and preclinical programs, partly offset by lower rusfertide trial costs


Company press release: ID:nACSrmDx0a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 License and Collaboration Revenue

$274.41 mln

Q3 EPS

$3.07

Q3 Net Income

$220.02 mln

Q3 Income from Operations

$218.33 mln

Q3 Operating Expenses

$56.08 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Protagonist Therapeutics, Inc. is $175.50, about 22.4% above its November 4 closing price of $143.37

  • The stock recently traded at 860 times the next 12-month earnings vs. a P/E of 95 three months ago


Reuters Recommended Reads

  • Nov 3 - Amgen Q3 revenue beats expectations on higher volumes

  • Nov 2 - Vertex Pharmaceuticals' Q3 revenue slightly beats estimates, outlook raised

  • Nov 3 - Amgen posts higher-than-expected third quarter results, but shares dip


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Protagonist Therapeutics

See all news